AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9557911
Drug: Esmolol 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 4.0 mg.kg(‐1) IV given 90 secs prior to tracheal intubation
Trial: 9557911
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.5 ml. 10kg(‐1) prior to eye bandaging and tracheal extubation
Trial: 2758870
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g (i.m.) every 12 h
Trial: 7769502
Drug: Quinapril hydrochloride,
RxNorm normalized name: Quinapril Hydrochloride, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril hydrochloride, once a day for 8 weeks, with optional titration to a higher dose after 4 weeks based on DBP response.
Trial: 581116
Drug: Micronized oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized oestradiol (1, 2 or 4 mg)
Trial: 28328303
Drug: 11 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 sessions of cell phone-delivered smoking cessation treatment
Trial: 24852505
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment (specific, individualized postural and movement retraining, stretching, and functional weight‐bearing, strengthening exercises)
Trial: 15292108
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine (2 g/d) + acetyl-L-carnitine (1 g/d)
Trial: 15292108
Drug: L-carnitine/acetyl-L-carnitine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine/acetyl-L-carnitine + 1 x 30-mg cinnoxicam suppository every 4 days
Trial: 12008655
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation
Trial: 25421879
Drug: Nebulized sodium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized sodium nitrite (AIR001) at a maximum tolerated dose (MTD) of 90 mg administered every 8 hours for 6 days
Trial: 25421879
Drug: Nebulized sodium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized sodium nitrite (AIR001) at higher dosage levels (120 mg and 176 mg)
Trial: 25698164
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) for PTSD
Trial: 7980302
Drug: Amniotomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotomy plus oxytocin infusion
Trial: 4850376
Drug: oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of digoxin (0.25 mg)
Trial: 4850376
Drug: intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of digoxin (0.25 mg)
Trial: 4850376
Drug: urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urinary excretion of digoxin
Trial: 23733488
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg saffron tablets for 7 days
Trial: 23733488
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg saffron tablets for 7 days
Trial: 24381222
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS)
Trial: 22873342
Drug: Antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drugs
Trial: 22258269
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS) with antiretroviral drugs
Trial: 22258269
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS) without antiretroviral drugs
Trial: 2314405
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine surfactant (20-40 mg/kg in group 1, 40-50 mg/kg in group 2)
Trial: 20870753
Drug: Nebulized gentamicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized gentamicin, 80 mg, twice daily for 12 months
Trial: 15223674
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (400 mg four times per day)
Trial: 9642893
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (STD)
Trial: 7702421
Drug: Captopril treatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril treatment
Trial: 2071264
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of garlic powder for four weeks
Trial: 6868954
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of myoinositol daily for 2 months
Trial: 21244601
Drug: Concurrent subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent subcutaneous interleukin‐2 (IL‐2), interferon‐α2b (IFN‐α) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Trial: 21275334
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy CD creation intervention
Trial: 12538369
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin E emulsion (all‐rac‐alpha‐tocopherol)
Trial: 24077370
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training sessions (twice per week) + in-water training
Trial: 15738535
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide)
Trial: 29168107
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy
Trial: 28259855
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid regimen (≤3.0 L in the first 24 hours)
Trial: 28259855
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid regimen (≥5.4 L in the first 24 hours)
Trial: 19226541
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) used for less than the study duration
Trial: 15569202
Drug: Alternative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapy use
Trial: 11022070
Drug: 3 intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intra-articular injections of 40 mg triamcinolone acetonide
Trial: 11022070
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL physiological saline solution (placebo)
Trial: 9288302
Drug: Caldwell‐Luc (C‐L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caldwell‐Luc (C‐L) operations
Trial: 8143886
Drug: zolpidem, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zolpidem, 10 mg for 2 weeks (nights 8-21)
Trial: 3046587
Drug: Multiple insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple insulin injections (MI)
Trial: 28681550
Drug: AZL-M/CLD 40/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M/CLD 40/12.5 mg/d (initial dose, could be uptitrated to 80/25 mg)
Trial: 15502020
Drug: S(+)-ketamine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)-ketamine (75 microg/kg bolus followed by continuous infusion of 1.25 microg . kg(‐1) . min(‐1) for 48 h)
Trial: 31597485
Drug: Label treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Label treatments (two levels)
Trial: 11903525
Drug: Intravenous valproate
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous valproate
Trial: 17054858
Drug: Autologous cytokine-induced
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous cytokine-induced killer cell (CIK) fusion (1.1 - 1.5 x 10^10) via peripheral vein or hepatic artery, administered once every 3 - 4 weeks for 4 times, then once every 4 weeks for 4 times
Trial: 8839716
Drug: Slow Rotation
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow Rotation (SR) chemotherapy
Trial: 8839716
Drug: Rapid Rotation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Rotation (RR) chemotherapy
Trial: 1311152
Drug: Self-help dietary
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help dietary intervention for individuals responsible for meal preparation
Trial: 25209738
Drug: Continuous drisapersen
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous drisapersen 6 mg/kg
Trial: 25209738
Drug: Intermittent drisapersen
RxNorm normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent drisapersen 6 mg/kg
Trial: 22732469
Drug: Cobicistat (COBI)
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cobicistat (COBI) 150 mg QD for 7 days
Trial: 22732469
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (RTV) 100 mg QD for 7 days
Trial: 11534317
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Dalteparin) at a dose of 200 I.E./kg body weight/d
Trial: 11534317
Drug: Unfragmented heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfragmented heparin
Trial: 9508182
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg subcutaneously every 4 weeks; n = 69)
Trial: 27546817
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 1.5 mg with perindopril 2-4 mg (active treatment)
Trial: 12221157
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (60 micro g)
Trial: 9865236
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for the same schedule
Trial: 23446658
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight loss (BWL) treatment
Trial: 24899570
Drug: Oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation containing hyaluronic acid (Oralvisc®)
Trial: 19164788
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg bolus followed by continuous infusion for 48 hours)
Trial: 24105697
Drug: Placebo (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (bolus and infusion)
Trial: 19164788
Drug: Lidocaine (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (lower doses)
Trial: 15306109
Drug: Cialis 20
RxNorm normalized name: Cialis 20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cialis 20 mg taken on demand
Trial: 9498886
Drug: Propofol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.0 mg/kgxh
Trial: 9498886
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg/kgxh
Trial: 9498886
Drug: Propofol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kgxh
Trial: 9498886
Drug: Propofol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.1 mg/kg bolus followed by 1.0 mg/kgxh
Trial: 8192438
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of oral acyclovir daily
Trial: 8192438
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of oral acyclovir daily
Trial: 26823552
Drug: Ketoanalogue‐supplemented vegetarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoanalogue‐supplemented vegetarian very low‐protein diet (KD) (0.3 g/kg vegetable proteins and 1 cps/5 kg ketoanalogues per day)
Trial: 26823552
Drug: Conventional low‐protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional low‐protein diet (LPD) (0.6 g/kg per day)
Trial: 24401580
Drug: P(cv‐a) CO2
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P(cv‐a) CO2 guided fluid therapy (group P)
Trial: 24401580
Drug: ScvO2 guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ScvO2 guided fluid therapy (group S)
Trial: 26130344
Drug: TXA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA group (2 intravenous injections of 1 g TXA pre- and post-operatively)
Trial: 22269195
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mouth rinse with no antiseptic agents)
Trial: 15662146
Drug: d-methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-methylphenidate hydrochloride (d-MPH) 10 mg twice-a-day
Trial: 11696143
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg x kg(‐1) 0.2% ropivacaine + clonidine 2 microg x kg(‐1)
Trial: 11696143
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg x kg(‐1) 0.2% ropivacaine
Trial: 11074735
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (conjugated equine estrogens alone or in combination with progestins)
Trial: 3932228
Drug: HB 420
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HB 420 (1.75 mg)
Trial: 3932228
Drug: HB 419
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HB 419 (2.5 mg)
Trial: 12241543
Drug: Prednisolone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (single 50 mg dose)
Trial: 7587422
Drug: Inhaled salmeterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol, 50 micrograms twice a day for seven doses
Trial: 2262371
Drug: Two hyperthermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two hyperthermia treatments
Trial: 30756527
Drug: 120 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/d ifenprodil
Trial: 30756527
Drug: 60 mg/d
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/d ifenprodil
Trial: 30391912
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) administration
Trial: 16459945
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical care plus compliance therapy (4-6 sessions, 60 minutes each)
Trial: 12856387
Drug: E5564 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5564 (all doses)
Trial: 10391557
Drug: Intraoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiation therapy (IORT) of 25 Gy
Trial: 10391557
Drug: Intraoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiation therapy (IORT) of 12-20 Gy
Trial: 1515884
Drug: 44 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 mg/kg of VP‐16 + 103 mg/kg CY followed by 12 Gy TBI (autologous marrow recipients)
Trial: 1515884
Drug: 36 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg/kg of VP‐16 + 67 mg/kg CY followed by 12 Gy TBI (allogeneic marrow recipients)
Trial: 1515884
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of etoposide and cyclophosphamide with TBI
Trial: 1515884
Drug: Dose limiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose limiting toxicities
Trial: 24766166
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages
Trial: 25187903
Drug: Endosseous implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endosseous implants with straight emergence profile, ZirTi surface, 3.3 to 5 mm diameter, and 8.5 to 13 mm length
Trial: 21812893
Drug: Rosiglitazone/Metformin (Rosi/Met,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone/Metformin (Rosi/Met, 4/1000 mg)
Trial: 17998769
Drug: Cilnidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (10 mg)
Trial: 29311072
Drug: Cefiderocol 100
RxNorm normalized name: cefiderocol 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefiderocol 100 mg
Trial: 29311072
Drug: Cefiderocol 250
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 250 mg
Trial: 29311072
Drug: Cefiderocol 2000
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 2000 mg
Trial: 29311072
Drug: Cefiderocol 1000
RxNorm normalized name: cefiderocol 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefiderocol 1000 mg q8h
Trial: 29311072
Drug: Cefiderocol 2000
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 2000 mg q8h
Trial: 12488964
Drug: Structured group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured group treatment and teaching programmes for Type I diabetes
Trial: 12488964
Drug: Structured group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured group treatment and teaching programmes for non-insulin dependent Type II diabetes
Trial: 12488964
Drug: Structured group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured group treatment and teaching programmes for hypertension
Trial: 12488964
Drug: Phased approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phased approach defining sequential stages of a continuum of increasing evidence
Trial: 10512131
Drug: IL-2 alone
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 alone at 6 x 10(6) Cetus units/m2 3 days weekly
Trial: 2022713
Drug: Daily metGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily metGH
Trial: 7075659
Drug: Indalpine (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indalpine (a selective 5‐HT uptake inhibitor) administered for 3 days
Trial: 15456080
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day)
Trial: 15456080
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day) plus amantadine (200 mg per day)
Trial: 5067672
Drug: Inert capsule
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert capsule (control)
Trial: 25226826
Drug: Echium oil
RxNorm normalized name: Echium plantagineum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echium oil (10 g daily providing 1.2 g of SDA)
Trial: 21646672
Drug: Hospital-specific factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-specific factors affecting blood pressure treatment
Trial: 9523054
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium infusion
Trial: 19199498
Drug: Low-dose magnesium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose magnesium infusion
Trial: 19199498
Drug: High-dose magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose magnesium infusion
Trial: 15544588
Drug: Loratadine 5
RxNorm normalized name: loratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 5 mg/day (2.5 mg/day for children ≤24 months of age)
Trial: 3365283
Drug: Indalpine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indalpine (50 mg/d and 150 mg/d)